Skip to main content

Press releases | August 24, 2020

Fried Frank acted as counsel to BofA Securities as financial advisor to Forbius Biologics Inc. (Forbius) in its acquisition by Bristol Myers Squibb (BMS). Forbius is clinical-stage protein engineering company that designs and develops biotherapeutics for the treatment of cancer and fibrotic diseases. Under this transaction, BMS would acquire Forbius' portfolio of highly selective and potent inhibitors of TGF-beta 1 and 3, which are key mediators of immunosuppression and fibrosis.

The Fried Frank team was led by partner Philip Richter. 


This communication is for general information only. It is not intended, nor should it be relied upon, as legal advice. In some jurisdictions, this may be considered attorney advertising. Please refer to the firm’s data policy page for further information.